A partnership agreement has been signed by BIA Separations, a biochromatography development and manufacturing company, and Nuvonis Technologies, a biotech company, to support the production of vaccine and gene therapy.
Partnership
Through this partnership, the companies will aim to offer solutions to meet the growing demand for vaccine and gene therapy production and tackle the challenges associated with managing the upstream/downstream process interface.
Customers will be offered an integrated service combining Nuvonis’ Vero cell bank with BIA Separation’s CIM monolithic column purification products, along with both companies’ understanding of the upstream/downstream process development. Through this approach it will be possible to create targeted solutions to improve manufacturing process execution, for the development of manufacturing procedures for gene therapy, oncolytic vaccines, exosomes and similar biomolecules.
“The interface between upstream and downstream bioprocessing is one of the most challenging technical areas remaining in the field, and where most production problems arise,” commented Aleš Štrancar, CEO of BIA Separations. “I look forward to seeing our teams working together to bring effective solutions to clients of any size — small, medium and large.”
“Choosing a well characterised Vero cell substrate and designing a simple high yield purification process is an important strategic element to most vaccine and gene therapy companies,” said Josef Poandl, Chairman of Nuvonis Technologies’ board. “By working together with BIA Separations, we will be able to offer unique solutions to improve production.”